Krukenberg tumor

Jump to navigation Jump to search
Krukenberg tumor
Krukenberg tumor
ICD-10 C56
ICD-9 183
ICD-O: 8490/6
DiseasesDB 30081
MeSH C04.557.470.200.025.415.410

WikiDoc Resources for Krukenberg tumor

Articles

Most recent articles on Krukenberg tumor

Most cited articles on Krukenberg tumor

Review articles on Krukenberg tumor

Articles on Krukenberg tumor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Krukenberg tumor

Images of Krukenberg tumor

Photos of Krukenberg tumor

Podcasts & MP3s on Krukenberg tumor

Videos on Krukenberg tumor

Evidence Based Medicine

Cochrane Collaboration on Krukenberg tumor

Bandolier on Krukenberg tumor

TRIP on Krukenberg tumor

Clinical Trials

Ongoing Trials on Krukenberg tumor at Clinical Trials.gov

Trial results on Krukenberg tumor

Clinical Trials on Krukenberg tumor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Krukenberg tumor

NICE Guidance on Krukenberg tumor

NHS PRODIGY Guidance

FDA on Krukenberg tumor

CDC on Krukenberg tumor

Books

Books on Krukenberg tumor

News

Krukenberg tumor in the news

Be alerted to news on Krukenberg tumor

News trends on Krukenberg tumor

Commentary

Blogs on Krukenberg tumor

Definitions

Definitions of Krukenberg tumor

Patient Resources / Community

Patient resources on Krukenberg tumor

Discussion groups on Krukenberg tumor

Patient Handouts on Krukenberg tumor

Directions to Hospitals Treating Krukenberg tumor

Risk calculators and risk factors for Krukenberg tumor

Healthcare Provider Resources

Symptoms of Krukenberg tumor

Causes & Risk Factors for Krukenberg tumor

Diagnostic studies for Krukenberg tumor

Treatment of Krukenberg tumor

Continuing Medical Education (CME)

CME Programs on Krukenberg tumor

International

Krukenberg tumor en Espanol

Krukenberg tumor en Francais

Business

Krukenberg tumor in the Marketplace

Patents on Krukenberg tumor

Experimental / Informatics

List of terms related to Krukenberg tumor

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Your Name

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

Overview

Krukenberg's tumor is a rare metastatic signet ring cell adenocarcinoma of the ovary.[1]

Historical Perspective

  • Krukenberg's tumor was first reported as a new type of primary ovarian malignancy by Friedrich Ernst Krukenberg (1871–1946), a German physician, in 1896 and were later confirmed to be of metastatic gastrointestinal tract origin.

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

  • [Disease name] may be caused by either [cause1], [cause2], or [cause3].
  • [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
  • There are no established causes for [disease name].

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected with [disease name] than [gender 2].
  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease name].
  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
  • Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

Case Studies

Case #1

References

  1. Al-Agha OM, Nicastri AD (2006). "An in-depth look at Krukenberg tumor: an overview". Arch Pathol Lab Med. 130 (11): 1725–30. doi:10.1043/1543-2165(2006)130[1725:AILAKT]2.0.CO;2. PMID 17076540.